Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

Lancet

Volumn 349, Issue 9057, 1997, Pages 995-996

  Carr, Andrew ^a,b   Cooper, David A ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; VIRUS IMMUNITY;

EID: 0030945427     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62892-9     Document Type: Article

References (5)

1. Fukuda R, Ishimura N, Nguyen TX, et al. The expression of IL-2, IL-4 and interferon gamma (IFN-g) mRNA using liver biopsies at different phases of acute exacerbations of chronic hepatitis B. Clin Exp Immunol 1995; 100: 446-51.
2. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-23.
3. Danner SA, Carr A, Leonard J, et al. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
4. Carr A, Emery S, Kelleher A, Law M, Cooper DA. CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retroviral 1996; 13: 320-26.
5. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of HIV-infected subjects treated with a HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-29.